Dashboard
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
With a fall in Net Profit of -25.41%, the company declared Very Negative results in Jun 25
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 13 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.96
-194.88%
3.18
Total Returns (Price + Dividend) 
SINTX Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is SINTX Technologies, Inc. technically bullish or bearish?
As of 4 September 2025, the technical trend for SINTX Technologies, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mixed signal with weekly mildly bullish and monthly mildly bearish readings. The KST is bullish on the weekly and mildly bullish on the monthly, while the OBV is bullish monthly but only mildly bullish weekly. Dow Theory presents a mildly bearish view on the weekly but mildly bullish on the monthly. In terms of performance, SINTX has outperformed the S&P 500 over the past month with a return of 32.70% compared to the S&P's 2.33%, and it has also shown a positive year-to-date return of 20.57% versus the S&P's 12.22%. However, over longer periods, the stock has significantly underperformed, with a 3-year return of -99.95% com...
Read MoreIs SINTX Technologies, Inc. overvalued or undervalued?
As of 29 March 2023, the valuation grade for SINTX Technologies, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 1.17, an EV to Sales ratio of 0.43, and a staggering ROCE of -822.40%. In comparison to its peers, SINTX Technologies has a P/E ratio of -1.6293, while Vivos Therapeutics, Inc. and NeuroMetrix, Inc. have P/E ratios of -2.0072 and -1.2085, respectively, suggesting that SINTX is relatively better positioned among its risky peers but still reflects significant financial challenges. Recent stock performance shows that while SINTX had a strong 1-month return of 32.70%, it lagged behind the S&P 500's 2.33% return over the same period, reinforcing the notion of its overvaluation amidst a broader market recovery....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 2 Schemes (1.67%)
Held by 4 Foreign Institutions (0.07%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -50.00% vs -20.00% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 0.00% vs -35.29% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 11.54% vs 62.50% in Dec 2023
YoY Growth in year ended Dec 2024 is -32.53% vs 30.83% in Dec 2023






